Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Vascular Diseases 1Pathologic Processes 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Liver Neoplasms 1Liver Diseases 1Leukemia, Myeloid, Acute 1Immunoproliferative Disorders 1Hemorrhagic Disorders 1Hematologic Diseases 1Gliosarcoma 1Glioblastoma 1Digestive System Neoplasms 1Digestive System Diseases 1Cardiovascular Diseases 1Carcinoma 1Blood Protein Disorders 1

Interventions

relacorilant 1pembrolizumab 1ficlatuzumab 1Pemetrexed 1MRX-2843 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pathologic Processes × ficlatuzumab × Clear all
NCT00969410 2012-04-12

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
19 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡